Advertisement

Tumors of the Central Nervous System

  • Aaron C. Jessop
  • Ronald C. Walker
  • Dominique Delbeke
Chapter

Abstract

Malignant cerebral tumors represent a small percentage (approximately 2%) of all malignancies, but have severe prognosis due to high morbidity and mortality. According to the American Cancer Society, in 2007 there were 23,300 new benign cerebral tumors and 20,500 new malignant cerebral tumors diagnosed in the United States, with an estimated number of resulting deaths of 12,760. Malignancies of the central nervous system (CNS) are the second most common malignancy in patients under the age of 20 (after hematologic malignancies) and are the leading cause of death from solid tumors in children and the third leading cause of death from cancer in the 15- to 34-year-old age group.

Keywords

Positron Emission Tomography Acquire Immune Deficiency Syndrome Primary Central Nervous System Lymphoma Central Nervous System Lymphoma Cerebral Metastasis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43–66.CrossRefPubMedGoogle Scholar
  2. 2.
  3. 3.
    Buckner JC, Brown PD, O′Neill BP, Meyer FB, Wetmore CJ, Uhm JH. Central nervous system tumors. Mayo Clin Proc 2007;82:1271–1286.CrossRefPubMedGoogle Scholar
  4. 4.
    Norden AD, Wen PY. Glioma therapy in adults. Neurologist 2006;12:279–292.CrossRefPubMedGoogle Scholar
  5. 5.
    Chen W. Clinical applications of PET in brain tumors. J Nucl Med 2007;48:1468–1481.CrossRefPubMedGoogle Scholar
  6. 6.
    Chugani HT, Phelps ME, Mazziotta JC. Positron emission tomography study of human brain functional development. Ann Neurol 1987;22:487–497.CrossRefPubMedGoogle Scholar
  7. 7.
    Di Chiro G. Positron emission tomography using [18F] fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool. Invest Radiol 1987;22:360–371.CrossRefPubMedGoogle Scholar
  8. 8.
    Pirotte BJ, Lubansu A, Massager N, Wikler D, Goldman S, Levivier M. Results of positron emission tomography guidance and reassessment of the utility of and indications for stereotactic biopsy in children with infiltrative brainstem tumors. J Neurosurg 2007;107:392–399.CrossRefPubMedGoogle Scholar
  9. 9.
    Pirotte B, Goldman S, Massager N, David P, Wikler D, Vandesteene A, Salmon I, Brotchi J, Levivier M. Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas. J Nucl 2004;45:1293–1298.Google Scholar
  10. 10.
    Pirotte B, Goldman S, Van Bogaert P, David P, Wikler D, Rorive S, Brotchi J, Levivier M. Integration of [11C]methionine-positron emission tomographic and magnetic resonance imaging for image-guided surgical resection of infiltrative low-grade brain tumors in children. Neurosurgery 2005;57(1 Suppl):128–139.CrossRefPubMedGoogle Scholar
  11. 11.
    Hustinx R, Pourdehnad M, Kaschten B, Alavi A. PET imaging for differentiating recurrent brain tumor from radiation necrosis. Radiol Clin North Am 2005;43:35–47.CrossRefPubMedGoogle Scholar
  12. 12.
    Terakawa Y, Tsuyuguchi N, Iwai Y, Yamanaka K, Higashiyama S, Takami T, Ohata K. Diagnostic accuracy of 11C-Methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med 2008; 49:694–699.CrossRefPubMedGoogle Scholar
  13. 13.
    Griffeth LK, Rich KM, Dehdashti F, Simpson JR, Fusselman MJ, McGuire AH, Siegel BA. Brain metastases from non-central nervous system tumors: evaluation with PET. Radiology 1993;186:37–44.PubMedGoogle Scholar
  14. 14.
    Rohren EM, Provenzale JM, Barboriak DP, Coleman RE. Screening for cerebral metastases with FDG PET in patients undergoing whole-body staging of non-central nervous system malignancy. Radiology 2003;226:181–187.CrossRefPubMedGoogle Scholar
  15. 15.
    Shaman MA, Zak IT, Kupsky WJ. Best cases from the AFIP: Involuted sclerotic meningioma. Radiographics 2003;23:785–789.CrossRefPubMedGoogle Scholar
  16. 16.
    Smirniotopoulos JG, Murphy FM, Rushing EJ, Rees JH, Schroeder JW. From the archives of the AFIP patterns of contrast enhancement in the brain and meninges. Radiographics 2007;27:525–551.CrossRefPubMedGoogle Scholar
  17. 17.
    Podoloff DA, Ball DW, Ben-Josef E, Benson AB, Cohen SJ, Coleman RE, Delbeke D, Ho M, Ilson DH, Kalemkerian GP, Lee RJ, Loeffler JS, Macapinlac HA, Morgan RJ, Siegel BA, Singhal S, Tyler DS, Wong RJ. NCCN Task Force: Clinical Utility of PET in a Variety of Tumor Types Task Force. J Natl Compr Canc Netw 2009;7 Suppl 2:S1–S23. www.nccn.org/professionals/physician_gls/f_guidelines.asp Google Scholar
  18. 18.
    Bénard F, Romsa J, Hustinx R. Imaging gliomas with positron emission tomography and single-photon emission computed tomography. Semin Nucl Med 2003;33:148–162.CrossRefPubMedGoogle Scholar
  19. 19.
    Hustinx R, Smith RJ, Benard F, Bhatnagar A, Alavi A. Can the standardized uptake value characterize primary brain tumors on FDG-PET? Eur J Nucl Med 1999;26:1501–1509.CrossRefPubMedGoogle Scholar
  20. 20.
    Di Chiro G, DeLaPaz RL, Brooks RA, Sokoloff L, Kornblith PL, Smith BH, Patronas NJ, Kufta CV, Kessler RM, Johnston GS, Manning RG, Wolf AP. Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography. Neurology 1982;32:1323–1329.PubMedGoogle Scholar
  21. 21.
    Padma MV, Said S, Jacobs M, Hwang DR, Dunigan K, Satter M, Christian B, Ruppert J, Bernstein T, Kraus G, Mantil JC. Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol 2003;64:227–237.CrossRefPubMedGoogle Scholar
  22. 22.
    De Witte O, Levivier M, Violon P, Salmon I, Damhaut P, Wikler Jr D, Hildebrand J, Brotchi J, Goldman S. Prognostic value positron emission tomography with [18F]fluoro-2-deoxy-D-glucose in the low-grade glioma. Neurosurgery 1996;39:470–476; discussion 476–477.CrossRefPubMedGoogle Scholar
  23. 23.
    Meyer PT, Schreckenberger M, Spetzger U, Meyer GF, Sabri O, Setani KS, Zeggel T, Buell U. Comparison of visual and ROI-based brain tumour grading using 18F-FDG PET: ROC analyses. Eur J Nucl Med 2001;28:165–174.CrossRefPubMedGoogle Scholar
  24. 24.
    Borbély K, Nyáry I, Tóth M, Ericson K, Gulyás B. Optimization of semi-quantification in metabolic PET studies with 18F-fluorodeoxyglucose and 11C-methionine in the determination of malignancy of gliomas. J Neurol Sci 2006; 246:85–94.CrossRefPubMedGoogle Scholar
  25. 25.
    Delbeke D, Meyerowitz C, Lapidus RL, Maciunas RJ, Jennings MT, Moots PL, Kessler RM. Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. Radiology 1995;195:47–52.PubMedGoogle Scholar
  26. 26.
    Mohile NA, Abrey LE. Primary central nervous system lymphoma. Neurol Clin 2007; 25:1193–1207.CrossRefPubMedGoogle Scholar
  27. 27.
    Mohile NA, Deangelis LM, Abrey LE. The utility of body FDG PET in staging primary central nervous system lymphoma. Neuro Oncol 2008;10:223–228.CrossRefPubMedGoogle Scholar
  28. 28.
    Ciricillo SF, Rosenblum ML. Use of CT and MR imaging to distinguish intracranial lesions and to define the need for biopsy in AIDS patients. J Neurosurg 1990;73:720–724.CrossRefPubMedGoogle Scholar
  29. 29.
    Offiah CE, Turnbull IW. The imaging appearances of intracranial CNS infections in adult HIV and AIDS patients. Clin Radiol 2006;61:393–401.CrossRefPubMedGoogle Scholar
  30. 30.
    Hoffman JM, Waskin HA, Schifter T, Hanson MW, Gray L, Rosenfeld S, Coleman RW. FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS. J Nucl Med 1993; 34:567–575.PubMedGoogle Scholar
  31. 31.
    O’Doherty MJ, Barrington SF, Campbell M, Lowe J, Bradbeer CS. PET scanning and the human immunodeficiency virus-positive patient. J Nucl Med 1997;38:1575–1583.PubMedGoogle Scholar
  32. 32.
    Young RJ, Sills AK, Brem S, Knopp EA. Neuroimaging of metastatic brain disease. Neurosurgery 2005;57(5 Suppl):S10–23; discussion S1–4.PubMedGoogle Scholar
  33. 33.
    Nguyen TD, DeAngelis LM. Brain metastases. Neurol Clin 2007;25:1173–1192.CrossRefPubMedGoogle Scholar
  34. 34.
    Friedlander RM. Clinical practice. Arteriovenous malformations of the brain. N Engl J Med 2007; 356:2704–2712.CrossRefPubMedGoogle Scholar
  35. 35.
    Choi JH, Mohr JP. Brain arteriovenous malformations in adults. Lancet Neurol 2005;4:299–308.CrossRefPubMedGoogle Scholar
  36. 36.
    Bruzzi JF, Truong MT, Marom EM, Mawlawi O, Podoloff DA, Macapinlac HA, Munden RF. Incidental findings on integrated PET/CT that do not accumulate 18F-FDG. AJR Am J Roentgenol 2006;187:1116–1123.CrossRefPubMedGoogle Scholar
  37. 37.
    Coleman RE, Delbeke D, Guiberteau MJ, Conti PS, Royal DD, Weinreb JC, Siegel BA, Federle MF, Townsend DW, Berland LL. Concurrent PET/CT with an integrated imaging system: Intersociety dialogue from the joint working group of the American College of Radiology, the Society of Nuclear Medicine, and the Society of Computed Body Tomography and Magnetic Resonance. J Nucl Med 2005;46:1225–1239.PubMedGoogle Scholar
  38. 38.
    Delbeke D, Coleman RE, Guiberteau MJ, Brown ML, Royal HD, Siegel BA, Townsend DW, Berland LL, Parker JA, Hubner K, Stabin MG, Zubal G, Kachelriess M, Cronin V, Holbrook S. Procedure guideline for tumor imaging with 18F-FDG PET/CT. J Nucl Med 2006;47:885–895.PubMedGoogle Scholar
  39. 39.
    Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M, Sabel M, Steinbach JP, Heese O, Reifenberger G, Weller M, Schackert G, for the German Glioma Network. Long-term survival with glioblastoma multiforme. Brain 2007;130 (Pt 10):2596–2606.Google Scholar
  40. 40.
    Langleben DD, Segall GM. PET in differentiation of recurrent brain tumor from radiation injury. J Nucl Med 2000;41:1861–1867.PubMedGoogle Scholar
  41. 41.
    Otte A, Roelcke U, von Ammon K, Hausmann O, Maguire RP, Missimer J, Müller-Brand J, Radü EW, Leenders KL. Crossed cerebellar diaschisis and brain tumor biochemistry studied with positron emission tomography, [18F]fluorodeoxyglucose and [11C]methionine. J Neurol Sci 1998;156:73–77.CrossRefPubMedGoogle Scholar
  42. 42.
    Lippitz B, Cremerius U, Mayfrank L, Bertalanffy H, Raoofi R, Weis J, Böcking A, Büll U, Gilsbach JM. PET-study of intracranial meningiomas: Correlation with histopathology, cellularity and proliferation rate. Acta Neurochirurgica 1996;65:108–111.PubMedGoogle Scholar
  43. 43.
    Cremerius U, Bares R, Weis J, Sabri O, Mull M, Schröder JM, Gilsbach JM, Buell U. Fasting improves discrimination of grade 1 and atypical or malignant meningioma in FDG-PET. J Nucl Med 1997;38:26–30.PubMedGoogle Scholar
  44. 44.
    Henze M, Schuhmacher J, Hipp P, Kowalski J, Becker DW, Doll J, Mäcke HR, Hofmann M, Debus J, Haberkorn U. PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Try3-Octreotide: first results in patients with meningiomas. J Nucl Med 2001;42:1053–1056.PubMedGoogle Scholar
  45. 45.
    Rutten I, Cabay JE, Withoffs N, Lemaire C, Aerts J, Baart V, Hustinx R. PET/CT of skull base meningiomas using 2-18F-Fluoro-L-Tyrosine: Initial report. J Nucl Med 2007; 48:720–725.Google Scholar
  46. 46.
    Coope D, Cizek J, Eggers C, Vollmar S, Heiss W-D, Herholz K. Evaluation of primary brain tumors using 11C-Methionine PET with reference to a normal methionine uptake map. J Nucl Med 2007;48:1971–1980.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Aaron C. Jessop
    • 1
  • Ronald C. Walker
    • 1
  • Dominique Delbeke
    • 1
  1. 1.Department of Radiology and Radiological SciencesVanderbilt University Medical CenterNashvilleUSA

Personalised recommendations